Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.ACGN · Entity 110652 | SVP AND GENERAL COUNSEL | January 20, 2023 | February 02, 2023 |
| Prelude Therapeutics IncPRLD · Entity 5561 | CLO, CFO, Corp Sec. | February 04, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date January 20, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2033-01-20 | Direct | 25,400 |
Reported balance
After 2023-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 25,400 · Balance 25,400 F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Prelude Therapeutics Inc
Report date February 04, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2036-02-03 | Direct | 275,000 |
Reported balance
After 2026-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 275,000 · Balance 275,000 F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 5, 2026 21:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001752888-26-000002 · primarydocument.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · CLO, CFO, Corp Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:34 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-25-000960 · primarydocument.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · CLO, CFO, Corp Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 12:35 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 25,000 | $0.91 | $22,637.50 |
DisclosureSEC source: 0001562180-24-008532 · primarydocument.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · CLO, Interim CFO, Corp Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,400 F1 · price: 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.87 to $0.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:00 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001562180-24-004084 · primarydocument.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · CLO, Interim CFO, Corp Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-13 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 14, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001562180-24-002139 · primarydocument.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · Chief Legal Officer, Corp Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 2,400 | $5.39 | $12,936.00 |
DisclosureSEC source: 0001562180-23-004479 · primarydocument.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · Chief Legal Officer, Corp Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,400 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001562180-23-002144 · primarydocument.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · Chief Legal Officer, Corp Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 20, 2023 Filed Feb 2, 2023 20:08 UTC | Aceragen, Inc. ACGN · Entity 110652 | GrantStock Options (Right to Buy) · Derivative | 25,400 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001415889-23-001855 · form4-02032023_010247.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Underlying: Common Stock · 25,400 shares Expires 2033-01-20 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | Tax withholdingCommon Stock | 119,957 | $0.71 | $85,157.47 |
DisclosureSEC source: 0001415889-23-000765 · form4-01112023_020118.xml · nonDerivative · entry 2 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,695 F2 · shares: Represents the number of shares withheld by Issuer to cover tax obligations in connection with the grant of the shares of common stock. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 399,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000765 · form4-01112023_020118.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,652 F1 · shares: Represents shares of common stock granted under the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended and restated. The shares were granted pursuant to that certain Employment Continuation and Retention Bonus Letter Agreement, dated as of September 28, 2022, between the Issuer and Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 17:33 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001415889-22-007545 · form4-07072022_020709.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2032-07-06 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:44 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001415889-22-003752 · form4-04042022_020430.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 20:43 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-22-000793 · form4-01262022_050117.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 16:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001415889-21-003585 · form4-07122021_040706.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2031-07-08 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 16:09 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 7,630 | $1.36 | $10,377.56 |
DisclosureSEC source: 0001415889-21-001672 · form4-03292021_010343.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,434 F1 · shares: Restricted Stock Units ("RSUs") granted to Reporting Person on January 3, 2019 and January 10, 2020 were accelerated and became fully vested on March 23, 2021. The amount reported in Column 4 represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 24,050 RSUs on March 23, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 19:08 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 1,711 | $4.21 | $7,201.77 |
DisclosureSEC source: 0001179110-21-000561 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,064 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.1901 to $4.239 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported securities beneficially owned, 24,050 shares are represented by unvested RSUs. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 19:08 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001179110-21-000561 · edgar.xml · derivative · entry 2 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2031-01-08 F4 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 05, 2021 Filed Jan 11, 2021 20:15 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 1,465 | $3.91 | $5,722.00 |
DisclosureSEC source: 0001179110-21-000525 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,775 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.945 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported securities beneficially owned, 29,050 shares are represented by unvested RSUs. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:37 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001179110-20-008430 · edgar.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-07-21 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 21, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 21, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:56 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001179110-20-000565 · edgar.xml · derivative · entry 2 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-10 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 10, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:56 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000565 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,240 F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award. F2 · balance_after: Securities beneficially owned totaling 41,240 includes 7,665 shares of Issuer common stock owned and 33,575 of unvested RSU's held by the reporting person. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 08:07 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 1,603 | $1.78 | $2,853.98 |
DisclosureSEC source: 0001179110-20-000446 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,240 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported shares, 13,575 shares are represented by unvested RSUs. Read SEC document |
| January 07, 2020 Filed Jan 14, 2020 18:10 UTC Amendment | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 1,603 | $1.78 | $2,853.98 |
DisclosureSEC source: 0001179110-20-000560 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,240 F1 · deemedExecutionDate: The Form 4 filed on January 10, 2020 did not include the Deemed Execution Date in Column 2A and corresponding footnote disclosure. This amendment to the Form 4 is being filed to include this information for the reported transaction. F2 · deemedExecutionDate: In accordance with terms of the RSU agreement, the "sell to cover" provision is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act. F3 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · balance_after: Of the reported shares, 13,575 shares are represented by unvested RSUs. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 17:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001179110-19-008594 · edgar.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2029-07-09 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 9, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 9, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:14 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001179110-19-000528 · edgar.xml · derivative · entry 2 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2029-01-03 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 3, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:14 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 18,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000528 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,843 F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award. F2 · balance_after: Securities beneficially owned totaling 22,843 includes 4,743 shares of Issuer common stock owned and 18,100 of unvested RSU's held by the reporting person. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 09:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 4,000 | $3.05 | $12,200.00 |
DisclosureSEC source: 0001179110-18-014243 · edgar.xml · nonDerivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,743 Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 16:20 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001179110-18-011368 · edgar.xml · derivative · entry 1 Lim Bryant David · CIK 0001752888 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2028-09-10 F1 · derivative.exercise_date: The option was granted under the Company's 2013 Stock Incentive Plan. The option vests and becomes exercisable over a four-year period commencing on September 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on September 10, 2019 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.